Aussie Institute Urges Coverage Of Osteoporosis Drugs For Breast Cancer
This article was originally published in PharmAsia News
Health experts in Australia are calling on the government to cover the use of osteoporosis drugs for women with a high risk of breast cancer. The New South Wales Cancer Institute cited international trials that have demonstrated tamoxifen and raloxifene are effective in preventing breast cancer. The head of the institute said Australia's Pharmaceutical Benefits Scheme should place both drugs on its formulary even though they would cost the government $187.7 million. He said the expenditure would be cost-effective in the long run. (Click here for more
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.